drugset
drugset / Trial / NCT04675008

Central Nervous System(CNS) Efficacy of Dacomitinib

NCT04675008 ↗

Phase 2 Unknown 30 enrolled Samsung Medical Center
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.

Timeline

Start
2020-12-07
Primary completion
2022-09-01
Completion
2023-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DACOMITINIB ANHYDROUS Small molecule — —

Indications

metastatic malignant neoplasm in the brain non-small cell lung carcinoma